Media services

Philippines to receive 30 million doses of Novavax COVID-19 vaccine

A small basket filled with vials labeled “COVID-19 – Coronavirus vaccine” and medical syringes are placed over a Novavax logo in this illustration taken on November 29, 2020. Photo taken on November 29, 2020. (Reutes / Dado Ruvic / Illustration / Photo File)

MANILA – The Philippines expects to receive 30 million doses of the COVID-19 vaccine from Novavax Inc by July of next year, its foreign minister said on Monday, stepping up the country’s efforts to secure supplies to vaccinate more than 100 million people.

Despite consultations with many vaccine manufacturers, the Philippines has so far signed only one supply agreement, with the help of its private sector, to acquire 2.6 million doses of a vaccine developed by AstraZeneca.

It plans to purchase 25 million doses of a vaccine from Chinese company Sinovac Biotech for delivery by March and aims to obtain between four and 25 million doses of vaccine from Moderna and Arcturus Therapeutics Holdings Inc.

“Thirty million doses of Novavax vaccines made in India are possibly being insured without cash advance. It will be available by July 2021, ”Foreign Secretary Teodoro Locsin said in an interview with CNN. Philippines.

He said the information came from the Serum Institute of India, the world’s largest vaccine producer, and the terms of the supply deal could be signed before the end of the year.

There was no immediate comment from the institute, which in August entered into a supply and licensing agreement with Novavax Inc for the development and commercialization of its COVID-19 vaccine candidate.

Talks with Moderna, which has obtained emergency use authorization from the United States Food and Drug Administration, will begin next week, Locsin said.

With 459,789 infections and 8,947 deaths, the Philippines recorded the second highest number of infections and victims of COVID-19 in Southeast Asia after Indonesia. – Report by Karen Lema; Editing by Martin Petty

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *